Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma - Trial NCT05871021
Access comprehensive clinical trial information for NCT05871021 through Pure Global AI's free database. This Phase 2 trial is sponsored by Ludwig-Maximilians - University of Munich and is currently Not yet recruiting. The study focuses on Glioblastoma. Target enrollment is 146 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Dose escalation of radiation dose beyond the therapeutic standard
Interventional
radiation
Sponsor & Location
Ludwig-Maximilians - University of Munich
Timeline & Enrollment
Phase 2
Oct 01, 2023
Jan 01, 2027
Primary Outcome
OS
Summary
Glioblastoma is the most aggressive brain tumor and often recurs locally despite intensive
 treatment. Standard chemoradiotherapy with 60 Gy may not be sufficient to control the tumor,
 and dose escalation seems to be warranted, but causes more toxicity. To address this, the
 multicentric PRIDE trial employs two cycles of bevacizumab to achieve dose escalation
 isotoxically. The goal is improved survival without significantly increasing side effects.
 The study uses a simultaneous integrated boost with a total dose of 75 Gy in 2.5 Gy per
 fraction.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05871021
Non-Device Trial